HMG

Volume Pricing

Price per pack (10 vials). Discount applies to this compound only – no mix and match.

HMG — Dual Gonadotropin | FSH + LH Activity | 1:1 Ratio

Human Menopausal Gonadotropin (HMG) is a naturally derived gonadotropin preparation extracted from the urine of postmenopausal women, containing both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in a standardized 1:1 ratio. Each 75 IU vial delivers 75 IU of FSH activity and 75 IU of LH activity, along with trace amounts of human chorionic gonadotropin (hCG) inherent to the extraction process. As a compound that simultaneously engages two distinct gonadotropin receptor systems — FSHR and LHCGR — HMG occupies a unique position in reproductive endocrinology research. It is one of the few available tools for studying coordinated dual-gonadotropin signaling without the confounds of recombinant single-hormone preparations, and has been used in published research since the 1960s.

Why Dual Gonadotropin Activity Matters

Most gonadotropin research compounds are single-receptor agents. HCG activates LHCGR only; recombinant FSH activates FSHR only. HMG activates both simultaneously — reflecting the physiological state in which LH and FSH work in concert to drive gonadal function through the “two-cell, two-gonadotropin” model of steroidogenesis and gametogenesis.

The two-cell theory underlies why neither FSH nor LH alone can fully replicate the complete gonadal signaling environment. In males, FSH acts on Sertoli cells to support spermatogenesis structurally and metabolically, while LH acts on Leydig cells to drive testosterone production — which is then required by Sertoli cells for sperm maturation. In females, FSH drives follicular recruitment and granulosa cell proliferation, while LH supports theca cell androgen synthesis, which granulosa cells convert to estradiol. HMG activates both arms of this system in a single compound.

Unlike HCG — which provides only LH-like signaling — HMG’s FSH component delivers the Sertoli cell support that HCG cannot, making it essential in protocols where spermatogenesis induction, not just testosterone production, is the research endpoint.

Research Applications

HMG is used in studies examining:

• Spermatogenesis induction in hypogonadotropic hypogonadism (HH) models, particularly when HCG monotherapy has been insufficient
• Dual gonadotropin signaling dynamics and FSH/LH receptor crosstalk in gonadal tissue
• Sertoli cell function, structural gene regulation, and germ cell support under FSH stimulation
• Follicular recruitment, development, and oocyte maturation in female reproductive models
• Controlled ovarian stimulation (COS) protocols and comparative outcomes vs. recombinant FSH preparations
• Combined HCG + HMG protocols for HPG axis reactivation and fertility restoration research
• Dose-response characterization of gonadotropin-driven steroidogenesis and spermatogenesis timelines
• Two-cell, two-gonadotropin model studies examining coordinated FSH/LH receptor activation

Specifications

Reconstitution

HMG arrives as lyophilized powder and must be reconstituted with bacteriostatic water prior to use. Like HCG, it is dosed in International Units (IU). Use the formula:

Total IU ÷ Volume added (mL) = Concentration (IU/mL)

Example: 75 IU vial + 1mL BAC water = 75 IU/mL solution Example: 75 IU vial + 2mL BAC water = 37.5 IU/mL solution

Add bacteriostatic water slowly by angling the needle against the inside wall of the vial — do not inject directly onto the powder. Gently swirl to dissolve; do not shake. HMG is a glycoprotein hormone and agitation can degrade biological activity. Reconstituted HMG should be stored at 2–8°C and used within 28–30 days.

Protocol Notes

HMG is administered subcutaneously or intramuscularly, typically 2–3 times per week. In research models it is most commonly used in combination with HCG rather than as a standalone agent — HCG establishes testosterone production first, and HMG is added to provide the FSH component required to advance spermatogenesis when HCG alone is insufficient.

Typical research dosing framework:

• Standard dose: 75–150 IU per administration
• Frequency: 2–3 times weekly (common protocol: Monday / Wednesday / Friday or Monday / Thursday)
• Combination context: Often paired with HCG (1,500–5,000 IU, 2–3× weekly) in hypogonadotropic models
• Study duration: 12–24 months for spermatogenesis endpoints; shorter windows used for steroidogenic or folliculogenic endpoints

Commonly observed effects in research models:

• Gonadal: Increased testicular volume in hypogonadotropic male models; follicular development and rising estradiol in female models
• Endocrine: Elevated serum testosterone (via LH component); rising estradiol and inhibin B (FSH-driven)
• Injection site: Mild redness, swelling, or transient discomfort — generally self-resolving
• Other: Headache, bloating, and nausea reported in the literature; ovarian hyperstimulation (OHSS) is a known risk in female models at higher cumulative FSH exposure

Research Stacks

HMG is commonly paired in research settings with:

• HCG — HCG provides LH-like gonadal stimulation while HMG contributes FSH-like follicle-stimulating activity; co-administration protocols are studied to replicate the coordinated LH/FSH signaling environment required for folliculogenesis and spermatogenesis research models.
• Kisspeptin-10 — Kisspeptin drives upstream GnRH pulsatility at the hypothalamic level; combining it with HMG’s direct gonadotropin activity allows researchers to dissect hypothalamic versus pituitary contributions to reproductive axis regulation.

Purity Guarantee

Every batch is ≥99% purity. If you independently test your compound and the results don’t match — send us the COA and we’ll issue store credit, no questions asked.